Investigating Migraine-Like Behavior Using Light Aversion in Mice
August 11th, 2021
Rodents are not able to report migraine symptoms. Here, we describe a manageable test paradigm (light/dark and open field assays) to measure light aversion, one of the most common and bothersome symptoms in patients with migraines.
This method provides a preclinical behavioral surrogate for photophobia, which is a chief complaint of migraine patients. The main advantage of this technique is that the detection is automatic thus very convenient. Also, light aversion and anxiety can be distinguished by conducting these tests.
On day one, turn the light/dark assay apparatus on. Set the light intensity to 27, 000 lux. Put the dark insert into light/dark chamber.
Open the tracking software and set up a new protocol. In the new protocol setting, set the duration to 30 minutes. In the new analysis setting, set data bins by duration to 300 seconds.
In the new zone setting, choose predefined zones. Choose two, and then horizontal. Check if the chamber is divided into two equal sized zones horizontally for recording.
Prior to the testing, habituate the mice to the testing room for one hour, keeping the room light on so as not to disturb the mouses circadian rhythm. Ensure all the equipment for the light/dark assay is turned on allowing the mice to fully acclimate to the testing room environment. Select acquire data, enter the mouse IDs and start the protocol.
Pull the drawer outside of the sound attenuating cubicle to access the light/dark chamber and the dark insert. Gently place a mouse in the light zone of the chamber and push the drawer inside the cubicle. Ensure that the software detects the mouse immediately and begins to record activity.
Wait for the recording to automatically stop after 30 minutes. Return the mouse to its home cage. Clean the chamber and dark insert using alcohol odor germicidal disposable wipes to eradicate any olfactory cues left by the previous mouse.
On day four, repeat all the steps that were performed on day one. On day seven, repeat the steps performed on day one, but only until the habituation of the mice. After the habituation, administer the mice with CGRP intraperitoneal.
Then return mice to their home cages. After 30 minutes, resume the protocol and run the mouse in the light/dark chamber as mentioned earlier. Clean the chamber and dark insert as described previously.
On day 10, repeat all the steps performed on day one. Turn the apparatus on and set the light intensity to 27, 000 lux. Open the tracking software and set up a new protocol as demonstrated previously.
In the new zone settings, choose one followed by center. Set the periphery as 3.97 centimeters and the center as 19.05 by 19.05 centimeters. Habituate the mice to the testing room as demonstrated previously.
Administer the mice with CGRP intraperitoneal. Return the mice to their home cages. After 30 minutes, start the protocol.
Pull the pullout drawer outside of the sound attenuating cubicle and gently place a mouse in the middle of the open field chamber. Push the drawer inside of the cubicle. Track the behavior of the mouse for 30 minutes, then return mice to their home cages.
Clean the apparatus as demonstrated previously. Results revealed that intraperitoneal injection of CGRP significantly decreased the duration of time spent in the light zone in the light/dark assay in CD1 and C57 black 6J mice, but did not affect the time mice spent in the center in the open field assay in CD1 and C57 black 6J mice. Treatment with CGRP also increased the amount of time mice rested in the dark zone, but not in the light zone in both CD1 and C57 black 6J mice.
The optical stimulation of neurons in the posterior thalamic nuclei, led to a corresponding decrease in the duration mice spent in the light zone in the light/dark assay in channelrhodopsin-2 injected mice compared to control virus injected mice. An increase in the resting time in the dark zone but not in the light zone was also observed in the case of the channelrhodopsin-2 injected mice, as compared to the control virus injected mice. It's important to remember that when putting the mouse into the light/dark chamber, the mouse should be handled gently to avoid as much stress as possible.
This technique will pave the way to explore mechanisms underlying migraine and other photophobia related disorders, and test the preclinical efficacy for potential therapeutics.
View the full transcript and gain access to thousands of scientific videos
Overview
This study presents a manageable test paradigm to assess light aversion in rodents, a common symptom of migraines. The method distinguishes between light aversion and anxiety, providing a preclinical behavioral surrogate for photophobia.
Key Study Components
Area of Science
- Neuroscience
- Behavioral assays
- Preclinical models
Background
- Rodents cannot report migraine symptoms directly.
- Photophobia is a significant complaint among migraine patients.
- Existing methods for assessing light aversion are limited.
- This study aims to improve the assessment of light aversion in animal models.
Purpose of Study
- To develop a reliable method for measuring light aversion in rodents.
- To differentiate between light aversion and anxiety in behavioral tests.
- To provide a convenient and automatic detection technique.
Methods Used
- Light/dark assay apparatus set to 27,000 lux.
- Dark insert used in the light/dark chamber.
- Open field assays conducted alongside light/dark tests.
- Behavioral observations recorded automatically.
Main Results
- The method effectively measures light aversion in rodents.
- Light aversion can be distinguished from anxiety responses.
- Automatic detection simplifies the assessment process.
- Results align with common migraine symptoms reported by patients.
Conclusions
- This study provides a novel approach to studying migraine symptoms in preclinical models.
- The technique can enhance understanding of photophobia in migraines.
- Future research can build on this method to explore migraine mechanisms.
Frequently Asked Questions
Executive Industry Relevance
This method provides a preclinical behavioral surrogate for photophobia, a key symptom of migraine, enabling target validation in migraine therapeutics development. By distinguishing light aversion from anxiety, it improves mechanistic de-risking and predictive confidence in early discovery. The approach supports translational continuity from target engagement to phenotypic screening in migraine-relevant systems.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of CGRP-mediated pathways as a therapeutic hypothesis in migraine models.
- Operational Value: Provides a quantifiable, automated readout for assessing target engagement of migraine-relevant compounds.
- Predictive Value: Supports portfolio triage by differentiating true photophobia effects from nonspecific anxiety confounds.
Screening & Assay Development
- Scientific Value: Delivers standardized, reproducible behavioral metrics for compound screening in photophobia-related indications.
- Operational Value: Facilitates high-throughput compatibility through automated tracking and defined temporal bins (300-second intervals).
- Assay Readiness: Supports screening campaign scalability via pre-exposure habituation and adjustable light intensity (55–27,000 lux).
Translational & Preclinical Research
- Translational Value: Aligns with clinical photophobia endpoints, enabling reverse translation from rodent behavior to human migraine symptomatology.
- Preclinical Continuity: Supports risk-adjusted advancement decisions by confirming on-target effects independent of anxiety modulation.
- Mechanistic De-risking: Validates posterior thalamic nuclei as a druggable node in photophobia pathways via optogenetic stimulation.
Pipeline & Workflow Integration
The method fits within the discovery continuum from target validation through lead identification to preclinical efficacy testing in migraine-relevant models.
- Discovery Biology: Tests therapeutic hypotheses involving CGRP signaling and neural circuit modulation in photophobia pathways.
- Screening: Delivers automated, quantitative light/dark preference data enabling reliable compound evaluation across strains.
- Analytics: Generates time-in-light vs. time-in-dark metrics and resting behavior readouts for comparative condition analysis.
- Translational Research: Connects rodent photophobia responses to clinical migraine symptoms, supporting biomarker-aligned go/no-go decisions.
- Enterprise Reuse: Establishes a reusable photophobia screening platform applicable across migraine, post-traumatic headache, and sensory disorder programs.
Operational & Enterprise Impact
- Scientific Value: Increases target validation confidence by isolating photophobia-specific responses from anxiety-related behaviors.
- Operational Value: Ensures assay reproducibility through standardized habituation, lighting controls, and automated data acquisition.
- Strategic Value: Reduces false-positive rates in migraine screening, improving capital efficiency in lead identification.
- Portfolio Impact: Enables risk-adjusted prioritization of compounds based on dissociable effects on light aversion versus anxiety.
Implementation Considerations
- Requires expertise in rodent behavioral neuroscience and photophobia assay interpretation.
- Dependence on light/dark and open field apparatus with adjustable luminance and tracking software.
- Necessitates cross-team standardization of habituation protocols and light intensity settings.
- Involves adaptation considerations when translating across mouse strains (e.g., CD1 vs. C57BL/6J) or disease models.
- Limited to measuring light aversion as a surrogate; does not capture other migraine symptoms like allodynia or cortical spreading depression.
